CTLA4 UNDEREXPRESSION Detail (hg19) (CTLA4)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr2:204,718,611-204,738,688 |
| hg38 | chr2:203,853,888-203,873,965 |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
| Type | Database | ID | Link |
|---|---|---|---|
| Gene | MIM | ||
| HGNC | |||
| Ensembl | |||
| NCBI | |||
| Gene Cards | |||
| OncoKB |
| Type | Database | ID | Link |
|---|---|---|---|
| Variant | TogoVar | ||
| COSMIC | |||
| MONDO |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Tumor vaccines expressing Flt3 ligand synergize with CTLA-4 blockade to reject preimplanted melanoma | MMMP | Detail |
| In a phase II trial (n=72), anti-CTLA4 antibody ipilimumab + DTIC yielded a 14.3% tumor response rat... | MMMP | Detail |
| The combination of MART-1 peptide-pulsed DC and tremelimumab results in objective and durable tumor ... | MMMP | Detail |
| CD25 antibody leads to depletion of CD25+ Treg cells (immunosuppressive cells). CTLA4: co-inhibitory... | MMMP | Detail |
| The combination therapy induced tumor rejection and skin depigmentation in B cell-deficient and in C... | MMMP | Detail |
| In this phase I-II trial, there is no evidence to support a synergistic effect of CTLA-4 blockade pl... | MMMP | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr2:204,718,611-204,738,688
- Variant Type
- cnv
Genome browser